World Lung 2016

Subgroup Analyses from Randomized Phase 3 Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC (OAK)

Conference Correspondent - WCLC 2016 - Lung Cancer

Atezolizumab, a humanized anti–PD-L1 monoclonal antibody, is approved for the treatment of patients with metastatic non–small-cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. OAK is one of the 2 international, randomized, open-label clinical trials that demonstrated superior efficacy for atezolizumab over docetaxel. [ Read More ]

First-Line Afatinib versus Gefitinib in EGFR-Mutated Advanced NSCLC: Updated Overall Survival (OS) Analysis of LUX-Lung 7

Conference Correspondent - WCLC 2016 - Lung Cancer

Afatinib, an irreversible ErbB family blocker, and gefitinib, a reversible EGFR tyrosine kinase inhibitor, are approved for first-line treatment of advanced EGFR-mutated non–small-cell lung cancer (NSCLC). Researchers reported updated OS findings from a phase 2b trial (LUX-Lung 7) that compared afatinib versus gefitinib in first-line patients. [ Read More ]

Efficacy and Safety of Necitumumab Continuation After Triplet Therapy in Patients with EGFR-Expressing NSCLC (SQUIRE)

Conference Correspondent - WCLC 2016 - Lung Cancer

The SQUIRE study demonstrated that the addition of necitumumab to gemcitabine plus cisplatin improved overall survival in patients with metastatic squamous non–small-cell lung cancer (NSCLC). Researchers evaluated the clinical outcomes associated with this triplet regimen in a subset of patients in the SQUIRE trial whose tumors expressed an epidermal growth factor receptor (EGFR). [ Read More ]

Phase 3 Study of Alectinib vs Crizotinib in ALK-Positive NSCLC (J-ALEX)

Conference Correspondent - WCLC 2016 - Lung Cancer

Use of an ALK inhibitor is standard in patients with ALK-positive non–small-cell lung cancer (NSCLC). In this phase 3 study, researchers compared 2 ALK inhibitors: crizotinib and alectinib. This randomized trial was designed to demonstrate superior progression-free survival for alectinib compared with crizotinib in ALK-inhibitor–naïve ALK-positive NSCLC. [ Read More ]

Pembrolizumab + Carboplatin and Pemetrexed as First-Line Therapy for Advanced NSCLC (KEYNOTE-021 Cohort G)

Conference Correspondent - WCLC 2016 - Lung Cancer

Platinum-based chemotherapy with or without bevacizumab is standard first-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) without genetic aberrations. Pembrolizumab has demonstrated activity in PD-L1–positive advanced NSCLC. Cohort G of the phase 1/2 KEYNOTE-021 study compared pembrolizumab + carboplatin and pemetrexed (CP) with CP in patients with treatment-naive advanced nonsquamous NSCLC. [ Read More ]